| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3d7010c2ad0c55d1b9e57fa8d2d1fbad |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 |
| filingDate |
2018-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_277b859244efbf7eff2f8dad8ab98a61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a4b94c93e79fc3885dbe1f6e5738de9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be5fbdfb5e7077484fc4a7c7b4687625
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ddc6e936f0b1b8c20f7cc6719c47adf2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f465883d57e6d62c62926a58b93dd84
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_411a5819251fde67620e6746e6adeb1f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36398dc4db4cd75948a19686ce0fa065
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77143155c9457fb57917c399f35c7256
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cefa75435cabd9248b452f1468363218 |
| publicationDate |
2020-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3634988-A1 |
| titleOfInvention |
Erythropoietin and analogs for veterinary use |
| abstract |
Provided are various embodiments relating to feline erythropoietin (EPO) polypeptide analogs with one or more additional glycosylation sites and methods of producing and using the same to treat anemia in companion animals. Also provided are various embodiments relating to EPO polypeptides having a mutation in the second binding site, polypeptides comprising an extracellular domain of EPO receptor, and methods of using the same for treating polycythemia in mammals. |
| priorityDate |
2017-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |